Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by ALX Oncology

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Appoints Allison Dillon as Chief Business Officer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Pricing of Public Offering
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces Proposed Public Offering
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Realigns Executive Leadership Team
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Announces September Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
From ALX Oncology
Via GlobeNewswire
Tickers ALXO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.